Metabolic syndrome: what is it and what are the implications?

D. I. Shaw*, W. L. Hall and C. M. Williams
Hugh Sinclair Unit of Human Nutrition, School of Food Biosciences, University of Reading, Reading RG6 6AP, UK

Obesity and overweight are linked with a cluster of metabolic and vascular disorders that have been termed the metabolic syndrome. Although there is not yet a universally-accepted set of diagnostic criteria, most expert groups agree that the syndrome is characterised by impaired insulin sensitivity and hyperglycaemia, dyslipidaemia (elevated blood triacylglycerols with depressed HDL-cholesterol), abdominal obesity and hypertension. Based on existing published criteria estimates suggest that the syndrome affects a substantial percentage of the middle-aged and elderly populations of most European countries (10–20%) and confers increased risk of type 2 diabetes (2–8.8-fold) and CVD (1.5–6-fold), as well as having a marked effect on morbidity. Although the pathophysiology is incompletely understood, insulin resistance and abdominal obesity are central to subsequent abnormalities in circulating glucose and lipoproteins, and vascular function that lead to type 2 diabetes, atherosclerosis and CVD. The link between metabolic syndrome, type 2 diabetes and CVD, as well as inability to reverse the present rising rates of obesity, will lead to economically-un sustainable costs of health care in the next 10–20 years. Preventative strategies for metabolic syndrome are required to slow rates of progression and to reduce dependence on costly medical management. A notable development is recent evidence that shows that diet and exercise are more effective than drug treatment in preventing the development of type-2 diabetes in high-risk individuals. The LIPGENE project will investigate dietary fat quality as a strategy for the prevention of metabolic syndrome and identify food chain approaches that can support consumer attempts to alter their dietary patterns.

Metabolic syndrome: Prevalence: Gender: Pathophysiology: Definition

Metabolic syndrome: a multi-faceted disorder

The term metabolic syndrome (or syndrome X) was first put forward by Reaven (1988) to describe a cluster of disorders linked with obesity and hyperinsulinaemia, and associated with a markedly increased risk of type 2 diabetes and CVD. Current escalation in the global prevalence of obesity has led to renewed interest in this disorder and its implications for future rates of diabetes and CVD. Although a number of different sets of diagnostic criteria have been proposed for the metabolic syndrome (World Health Organization, 1999 (WHO criteria); Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001 (National Cholesterol Education Program (NCEP) criteria); European Group for the Study of Insulin Resistance, 2002), insulin resistance, hyperglycaemia, dyslipidaemia, central obesity and hypertension are generally agreed to be the five key features. However, these features are often accompanied by other related abnormalities of vascular function and lipoprotein metabolism (see Fig. 1). Most definitions require fulfilment of three of five key criteria, allowing for various spectra of presentation of the metabolic syndrome. Many authorities express the view that insulin resistance is the central pathological link amongst these risk factors, whilst other authorities believe that the metabolic syndrome is a consequence of the complications caused by obesity (Grundy, 2004a). Although central obesity is strongly associated with insulin resistance, it is clear that insulin resistance only occurs in approximately half of obese subjects (Nestel, 2004).

Abbreviations: NCEP, National Cholesterol Education Program; NCEP criteria, diagnostic criteria for the metabolic syndrome proposed by the NCEP Adult Treatment Panel III (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001); TAG, triacylglycerols; TRL, TAG-rich lipoprotein; WHO criteria, diagnostic criteria for the metabolic syndrome proposed by the World Health Organization (1999).

*Corresponding author: Ms D. Shaw, fax +44 118 9318703, email d.i.shaw@reading.ac.uk

Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 19 Jun 2019 at 11:25:20, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1079/PNS2005442

DOI:10.1079/PNS2005442
Insulin resistance and the disorders of the metabolic syndrome

Whether insulin resistance is the primary event in the development of the metabolic syndrome or arises as a consequence of obesity, it is clear that insulin resistance is an important factor in the associated disturbances in carbohydrate and lipid metabolism. In the metabolic syndrome, as in type 2 diabetes, the response to insulin is impaired, resulting in a compensatory hyperinsulinaemia. Over a period of time hyperinsulinaemia fails to compensate for impaired insulin action on glucose uptake and metabolism, with resulting hyperglycaemia. Although insulin is commonly recognised as a hormone involved in glucose metabolism, this hormone also has a critical role in lipid metabolism. Resistance to the actions of insulin on lipid metabolism underlies the typical dyslipidaemia of the metabolic syndrome, which is characterised by moderately-elevated blood triacylglycerols (TAG) and reduced HDL concentrations. Elevated circulating TAG are a result of an increase in TAG and VLDL synthesis and secretion from the liver. There is also reduced systemic clearance of TAG as a result of impaired insulin-mediated activation of lipoprotein lipase. This enzyme normally hydrolyses TAG in circulating chylomicrons and VLDL and enables uptake of fatty acids into peripheral tissues. It is therefore not surprising to observe that in addition to abnormalities in fasting lipoprotein concentrations there are marked elevations in circulating postprandial TAG concentrations following a fat-containing meal in individuals with the metabolic syndrome. This effect is frequently referred to as the TAG intolerance of metabolic syndrome and resembles the glucose intolerance observed when large carbohydrate doses are given to subjects with insulin resistance.

Insulin normally suppresses the activity of hormone-sensitive lipase, the enzyme that hydrolyses intracellular TAG in adipose tissue, leading to sustained release of fatty acids into the circulation and raised circulating NEFA levels. Hormone-sensitive lipase is elevated under fasted conditions and reduced under fed conditions as a result of inhibition by insulin. However, in insulin-resistant subjects hormone-sensitive lipase activity is not fully suppressed in the fed state and NEFA levels are elevated. Elevated NEFA have various deleterious effects (including stimulation of hepatic TAG and VLDL synthesis and competitive inhibition of peripheral tissue uptake of glucose) that further exacerbate insulin resistance-related glucose intolerance.

In the metabolic syndrome LDL concentrations may be normal, but the proportion of LDL as small dense LDL is increased; HDL-cholesterol concentrations are lower than normal but the proportion of small dense HDL is also increased. These qualitative abnormalities in circulating lipoproteins are a result of accelerated serum neutral-lipid exchange, mediated by a cholesteryl ester transfer protein and stimulated by the raised concentrations of TAG-rich lipoprotein (TRL) particles. Net transfer of TAG from TRL to HDL and LDL particles is promoted under these conditions; this process is followed by TAG hydrolysis on LDL and HDL, which results in formation of small dense cholesterol-rich particles. Small dense LDL particles are not effectively removed by the LDL receptor, are retained longer within the circulation and have a greater potential to infiltrate the artery wall. Small dense HDL is more rapidly catabolised than more buoyant HDL; over a period of time the accelerated catabolism of HDL particles leads to the low circulating HDL concentrations that typify the insulin-resistant subject. This collection of circulating lipoprotein abnormalities (low HDL, moderately-raised fasting TAG, elevated TRL remnant concentrations and raised small dense LDL) are referred to as the atherogenic lipoprotein phenotype, which when present confers a 2–5-fold increased risk of CVD (Cefalu, 2001; Cunnane & Griffin, 2002).

Hypertension is a common feature of the metabolic syndrome that has been explained by increased activity of the sympathetic nervous system as a result of hyperinsulinaemia. Furthermore, hypertriglyceridaemia, a key component of insulin-resistant dyslipidaemia, has been implicated in the endothelial dysfunction that occurs in insulin-resistant subjects. Raised TRL particles may lead to impaired-flow-mediated dilation, a vascular response that is critical to maintaining normal blood pressure. The mechanism for the effect of TRL is unclear, but may involve the production of reactive oxygen species and vasoactive molecules that could interact with endothelial NO-mediated vasodilation (van Oostrom et al. 2002). Importantly, adverse effects on blood flow and on endothelial function, secondary to insulin resistance, have the potential to further impair the transport of glucose and TRL to sites of their normal storage and utilisation, therefore heightening the states of dyslipidaemia and hyperglycaemia (Cefalu, 2001; van Oostrom et al. 2002).

The metabolic syndrome may also be characterised by the presence of pro-inflammatory conditions, microalbuminuria and hypercoagulability (World Health Organization, 1999). The Framingham Offspring Study (Wilson, 2004) has shown that haematological abnormalities, such as raised prothrombotic plasminogen activator inhibitor type 1, tissue plasminogen activator and fibrinogen, are associated with hyperinsulinaemia and hyperglycaemia. Studies (Cefalu, 2001) have also shown that improvement in insulin resistance is paralleled by improved metabolic abnormalities and by return of these haematological factors towards normal.
Definitions of the metabolic syndrome

Given the number of systems affected and the wide interindividual variability observed, it is not surprising that currently there is no universally-accepted definition of the metabolic syndrome. A universal definition for metabolic syndrome would enable more effective clinical diagnosis and allow global monitoring for the purpose of policy development and establishment of prevention programmes.

The NCEP Adult Treatment Panel III (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001), the World Health Organization (1999) and the European Group for the Study of Insulin Resistance (2002) have each defined the metabolic syndrome (Table 1). Each of the definitions includes a measure of obesity or central obesity, hypertension and dyslipidaemia. Insulin resistance is the main focus of the WHO criteria, whereas the NCEP definition (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001) does not include a direct measure of insulin resistance. The World Health Organization (1999) definition allows inclusion of individuals with diabetes, whereas this condition is not included in the other definitions discussed.

The inclusion of microalbuminuria has been questioned as a core component of the World Health Organization (1999) definition, as it is not usually present in individuals without diabetes (Laaksonen et al. 2002). Further points of discussion include the methods of measurement and the cut-off points used to define abnormality. The reliability and clinical applicability of measurements of insulin resistance has been widely debated. The most appropriate measure of central obesity, e.g. the use of waist:hip ratio or waist circumference, has been discussed in light of the fact that waist:hip ratio correlates with disease end points independently of waist measurement and BMI, whereas waist measurement correlates better with visceral fat deposits as measured by tomography (Laaksonen et al. 2002). The use of gender-specific cut-offs for abdominal obesity and HDL has also been questioned because a French longitudinal cohort study (Balkau et al. 2003) and the National Health and Nutrition Examination Survey III (Ford et al. 2002) have shown that risk for CVD increases with central adiposity independently of gender (Balkau et al. 2003).

A factor that needs urgent consideration is the inclusion of cut-off thresholds that take into account the differential susceptibility of ethnic subgroups such as African-Americans or the Asian population. Metabolic syndrome and its associated disease outcomes are highly prevalent in these groups, but current cut-off points may underestimate true prevalence, with an adverse consequence for prevention programmes. Tan et al. (2004) have investigated the use of the NCEP criteria in an Asian population using data from a cross-sectional national health survey involving 4723 men and women. They have proposed that the adverse impact of central obesity on insulin sensitivity occurs at a lower waist circumference in Asian groups than in Caucasian groups, and recommend the use of a lower cut-off value to reflect this difference.

Insulin resistance and abdominal obesity in the aetiology of the metabolic syndrome

The pathophysiology of the metabolic syndrome is poorly understood, largely because the close interrelationship...
between insulin resistance, obesity and lipid abnormalities precludes a clear identification of the primary pathological event(s). It has been suggested that a defect in the insulin signalling pathway may be a key mechanism in the development of the metabolic syndrome, particularly within specific tissues such as the liver, adipose tissue and muscle (Kohen-Avron et al. 2003). However, there are also data that suggest that the defects in insulin signalling are secondary to intracellular disturbances of carbohydrate and lipid utilisation in tissues, and that these disturbances arise when energy balance and body weight are disturbed. A better understanding of the pathophysiology of insulin resistance, and of the metabolic syndrome, would allow identification of predictive risk factors and enable effective dietary and lifestyle interventions to be devised.

Using traditional epidemiological approaches to disentangle the contribution of insulin resistance and central obesity to the development of the metabolic syndrome has proved to be extremely difficult, because these two factors are themselves so closely interlinked. The Bogalusa Heart Study (Chen et al. 1999) has investigated the prevalence of the metabolic syndrome amongst young parents and their offspring. The odds ratio for offspring having the same cluster of metabolic syndrome components as their father, mother, and both parents was found to be 7.2, 8.6 and 7.9 respectively. Furthermore, adverse parental insulin levels and BMI were shown to markedly increase the risk of their offspring developing metabolic syndrome. However, the risk attributed to parental insulin levels was found to be reduced when adjustment is made for parental BMI. This study has not only confirmed a familial trait for the metabolic syndrome but also suggests that parental obesity, and thereby associated hyperinsulinaemia in parents, may underlie this familial association.

There is substantial evidence from epidemiology to support the link between insulin resistance and the metabolic syndrome. In the Strong Heart Study (Resnick et al. 2003) non-diabetic American Indians (n 2283) were followed over 7.7 (sd 1.8) years and the prevalence of metabolic syndrome. In the Strong Heart Study (Resnick et al. 2003) has found that the prevalence of the metabolic syndrome is significantly increased (P < 0.001) in subjects with abdominal obesity (defined as a waist circumference of >880 mm in women and >1020 mm in men); insulin resistance is also more prevalent in individuals with abdominal obesity. A waist circumference of >890 mm in women and >1020 mm in men has been classed as the optimal predictor of the metabolic syndrome in the Insulin Resistance Atherosclerosis Study (Palaniappan et al. 2004), a prospective study that included subjects of various ethnic backgrounds (n 714, average 5.2-year follow-up), with logistic regression models adjusted for age, sex, study site, ethnicity and impaired glucose tolerance showing an odds ratio of 1.7/110 mm increase in waist circumference. Interestingly, impaired glucose tolerance was not found to be a useful predictor of the metabolic syndrome. These prospective data support the view that obesity precedes the development of the metabolic syndrome, although the fact that the study was not population based suggests that extrapolation to the general population should be done with some caution. Carr et al. (2004) have found that intra-abdominal fat and subcutaneous fat levels (measured by single-slice computer tomography) are higher in those subjects with the metabolic syndrome. Indeed, a strong positive correlation was found between intra-abdominal fat area and the number of criteria of the metabolic syndrome, with associated odds ratios of 2.1 and 1.97 for intra-abdominal and subcutaneous fat respectively. It is noteworthy that these associated odds ratios for abdominal and subcutaneous fat areas were shown to be greater than the odds ratio associated with a decrease in insulin resistance. Importantly, waist circumference was found to be more strongly correlated with intra-abdominal fat area (r 0.799) than with subcutaneous fat area (r 0.595). It is argued (Carr et al. 2004) that criteria for the metabolic syndrome should include measurement of waist circumference, which ensures that intra-abdominal fat area, a factor found to be independently associated with all criteria, is appropriately weighted in the diagnosis.

Although the epidemiological studies clearly show that both insulin resistance and obesity have clear associations with the metabolic syndrome, such data are unable to identify the causal pathway. The study carried out by Carr et al. (2004) shows that both insulin resistance and abdominal obesity are correlated with the metabolic syndrome. However, the authors suggest that as intra-abdominal fat is independently associated with all criteria, visceral adiposity may have a particular role in the pathophysiology of the metabolic syndrome. The role of adipose tissue, and of specific adipose tissue depots, in the disturbances of insulin and macronutrient metabolism in obesity is an exciting area of current research. Bioactive products of the adipocyte, such as TNFα, IL-6 and leptin, and reduced concentrations of adiponectin have been implicated in the aetiology of insulin resistance. The product of adipose tissue TAG hydrolysis, NEFA, also appears to play a primary role in disturbances in whole-body glucose and lipid metabolism (Grundy, 2004b).
A detailed discussion of adipose tissue biology and of the role of NEFA in insulin resistance and metabolic syndrome is beyond the scope of the present review. However, examination of these issues is provided by a number of recent reviews (Haber et al. 2002; Kraegen et al. 2002).

Prevalence of the metabolic syndrome

The incidence of obesity is rapidly increasing in the USA and Europe, and increases in obesity are also now being observed in developing countries (World Health Organization/Food and Agriculture Organization, 2003). It has been estimated that up to 80% of the 45–59-year-olds in eastern Europe may be obese, with the greatest prevalence being amongst women (James, 2004). Globally, 10% of the school-age children are overweight, with approximately 3% of these being clinically obese (Lobstein et al. 2004). The rapid rate of increase is of major concern. In parts of Europe an additional 1% of the children are becoming overweight each year (Lobstein et al. 2004). Indeed, throughout Asia, Latin America and parts of Africa, where previously there has been widespread undernutrition, obesity has increased 2–3-fold in the past decade (World Health Organization/Food and Agriculture Organization, 2003).

The risk of developing type 2 diabetes is up to 10-fold greater in those individuals with a BMI >30 kg/m² (Diabetes UK, 2004), and the current rise in obesity amongst children and adults is generating a worldwide epidemic of type 2 diabetes. Since 1996 the number of individuals diagnosed with diabetes in the UK has increased from 1.4 million to 1.8 million in 2004, with projections that it will reach three million by 2010 (Diabetes UK, 2004). The present rates of increase in obesity, and of type 2 diabetes, are indicative of an increased prevalence of metabolic syndrome. The need to confirm and quantify the accuracy of this prediction is of considerable importance, because of the high predictive value of metabolic syndrome for CVD and diabetes.

The lack of a universally-accepted definition is a limiting factor in attempts to quantify present rates of metabolic syndrome and the likely prevalence in the future. Estimates of prevalence vary considerably depending on the criteria used (Table 1). In one study of the same adult Finnish population the prevalence rates were reported to vary from 8.8% to 14.3%, depending on the definition used (Lakka et al. 2002). Fig. 2 provides a summary of prevalence rates recorded in recent European and US studies. Clearly, these studies indicate a greater prevalence of metabolic syndrome in the US population as compared with the European population, and this finding is consistent with the higher rates of obesity in the USA. However, the quality and consistency of the studies vary considerably and it is important to consider the types of populations included in these studies. The Spanish study (Ascáso et al. 2003) indicates a high prevalence rate (28.9%) in comparison with the other European studies (8.1–19.8%). However, the subjects were at greater risk than the general population since they were recruited from a primary care outpatient unit and the definition used to diagnose metabolic syndrome could be considered to lack rigour since only two criteria were required to be fulfilled.

The majority of the studies that have been reviewed confirm that independently of the criteria used the incidence of metabolic syndrome increases with age. Most studies that aim to assess the population incidence of the metabolic syndrome usually include adult subjects >18 years of age, although many studies use the 25–30 years age-range as the lower limit for inclusion. Importantly, the Bogalusa Heart Study has shown that the metabolic syndrome is present in children and young adults (Chen et al. 1999). Indeed, in a large group of multi-ethnic multi-racial 4–20-year-olds, using both the NCEP (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001) and World Health Organization (1999) definitions, the metabolic syndrome was shown to be present in 38.7 and 49.7% of moderately- and severely-obese groups respectively (Weiss et al. 2004). Within the EU fourteen million children are overweight, which includes three million obese children, and the epidemic of childhood obesity and overweight is accelerating. Currently, 10–20% of the children in northern Europe are overweight compared with a prevalence of 20–35% in southern Europe (International Obesity Task Force, 2004).

These statistics for children illustrate that in the future prevalence rates for metabolic syndrome are likely to be even higher than present rates in adult populations. Clearly, the inclusion of younger age-groups in population studies would result in an underestimation of overall prevalence in older age-groups. However, further studies in children and young adults are urgently required as a means of assessing the likely impact of rising rates of overweight and obesity on the metabolic syndrome in the future. A further point to consider is the use of age-truncated rates (35–65 years) to assess prevalence rates. Many studies include subjects only up to the age of approximately 65 years and thereby underestimate the true impact of metabolic syndrome in later years. With increasing life expectancy and many of the population living into their 8th decade, the present data underestimate the impact of lifestyle-related metabolic disturbance on human health and the likely future costs of health care.

There are marked ethnic variations in susceptibility to the metabolic syndrome. Prevalence amongst American Indians, for example, is estimated at 35% which is much
greater than estimates for other groups (Resnick et al. 2003). Additionally, Tan et al. (2004) have proposed that present cut-off points for waist circumference or BMI are likely to underestimate true prevalence rates in Asian Indians. Similarly, cut-offs for blood lipid profiles may give a false indication of lower rates of the metabolic syndrome for some groups, since black populations generally show more favourable lipid profiles than white populations relative to their actual risk of the metabolic syndrome (Weiss et al. 2004). In the study of Weiss et al. (2004), when data that account for the more favourable lipid profiles of black subjects are used, the prevalence of the metabolic syndrome and effect of obesity on risk are similar amongst the various races studied.

There is a lack of reliable population data on prevalence rates for metabolic syndrome from the developing world, but the data for obesity and diabetes are strongly suggestive of a growing incidence of the metabolic syndrome in these parts of the world. A factor that may predispose to even higher rates of obesity and type 2 diabetes in populations previously exposed to under-nutrition is the presence of a ‘thrifty genotype’ (Dowse & Zimmet, 1993; Kohen-Avramoglou et al. 2003). In societies in which food supply has been insecure, it is suggested that genotypes with the capacity to store large amounts of fat during times of plentiful supply will have tended to survive at the expense of less-thrifty genotypes. Thus, biological mechanisms that enable individuals to store fat will tend to be overrepresented in such societies, and during times of plentiful food supply will lead to greater capacity to become obese (Kohen-Avramoglou et al. 2003).

Many of the current findings for prevalence rates of metabolic syndrome are based on data from ongoing prospective studies of large European or American populations. Most of them were not initially set up to measure indicators of insulin sensitivity or central body fat distribution, and consequently many of the studies have used modified versions of the established risk factor criteria. More studies are needed that incorporate measurements in both sexes, high-risk ethnic groups and younger and older subjects and adhere to standardised criteria, using adjusted cut-off points where relevant.

The implications of the metabolic syndrome: CVD and type 2 diabetes

There is mounting evidence to suggest that the presence of the metabolic syndrome increases individual risk of type 2 diabetes and CVD, major causes of morbidity and mortality.

In a male Finnish population four definitions for the metabolic syndrome based on the WHO and NCEP criteria were used to assess the progression of the metabolic syndrome to type 2 diabetes. After a 4-year follow-up the odds ratio range for risk imposed by the metabolic syndrome was found to be 5.0–8.8. The WHO criteria predicted a 9-fold increased risk of development of type 2 diabetes for individuals with the metabolic syndrome. It was concluded that type 2 diabetes is closely related to the metabolic syndrome and could be considered an end-stage manifestation of the metabolic syndrome (Laaksonen et al. 2002).

In a prospective study of Pima Indians (n 1918; Hanson et al. 2002) with a median follow-up of 4-1 years the WHO criteria were found to be more sensitive and more specific at predicting development of type 2 diabetes than the NCEP criteria. The metabolic syndrome as defined by WHO criteria was found to confer a greater risk of progression to type 2 diabetes (odds ratio 3·58) than the NCEP criteria (odds ratio 2·09). This difference is likely to be a result of the emphasis in the WHO definition on presence of insulin resistance, compared with the NCEP definition that weights all components equally.

Although the link with type 2 diabetes is well established, the additional risk for CVD and CHD remains to be quantitatively established. A number of prospective studies that have assessed the outcome for CVD and CHD provide odds ratio estimates of between 1·5 and 6·0 in subjects who fulfil the criteria for metabolic syndrome (Fig. 3). As previously discussed, estimates of the impact on CVD will depend on the rigour of the criteria used to confer classification of metabolic syndrome. Fig. 3 shows that the odds ratios for CVD and CHD in individuals with the metabolic syndrome differ when the WHO (2·72) and NCEP (3·40) definitions are used in the same Finnish male study population (Lakka et al. 2002), although both clearly demonstrate an extent of risk that has an important public health impact. It is clear that the major public health focus should be to emphasise the powerful impact of the clustering of the five components of metabolic syndrome (insulin resistance, hyperglycaemia, dyslipidaemia, central obesity and hypertension) (Isomaa et al. 2001). Factor analysis has shown that there is an interdependence of the components and their clustering does not occur by chance (Nestel, 2004).

Data from studies that have investigated the effects of gender suggest that the presence of metabolic syndrome may confer a greater cardiovascular risk in women than in
There is little doubt that prevalence is increasing and that estimate of the prevalence of the metabolic syndrome, although present data make it difficult to provide a precise resistance, metabolic syndrome and CVD risk.

The development of a better understanding of insulin sensitivity and CVD risk conducted by the European study (2004) is an ongoing European multi-centre prospective study with 2000 subjects of 30–60 years of age, across thirteen countries that will provide important data for the development of a better understanding of insulin resistance, metabolic syndrome and CVD risk.

**Future approaches to the metabolic syndrome**

Although present data make it difficult to provide a precise estimate of the prevalence of the metabolic syndrome, there is little doubt that prevalence is increasing and that there are adverse impacts on human health. The present review has mainly emphasised the relationship between the metabolic syndrome and mortality rates for CVD, because mortality data is more readily available than other markers of health outcome. Morbidity caused by associated conditions such as eye disease, stroke risk, kidney problems and nerve damage, which have adverse impacts on the quality of life of individuals with diabetes and on the costs of health care, are less easily quantified. However, current estimates indicate that in the UK £3.5 × 10^9/year is spent on the treatment of diabetes and its complications alone, and expenditure is expected to rise by 10% by 2011 (Diabetes UK, 2004).

Although rates of obesity have quadrupled in many developed countries over the past 25 years, it is highly unlikely (even with the most extreme public health interventions) that present rates of obesity can be reversed in the same time period. Efforts to introduce lifestyle changes to reduce current rates of obesity and slow down the rate at which obesity is increasing in the developed and developing world must be stepped up. However, more achievable short-term measures that can reduce the adverse impact of obesity on human health must also be considered. A first step could be interventions to reduce the prevalence of metabolic syndrome. Although there are some difficulties in arriving at a precise definition of the metabolic syndrome, efforts in this direction should be encouraged, since a robust definition could provide a target for intervention in the public health programmes that must be mounted in the near future.

Further research is also needed to assess qualitative and quantitative changes in diet that could reduce the impact of overweight and obesity on metabolic syndrome and insulin resistance. An area of great interest is the impact of dietary fat quality on markers of the metabolic syndrome and the associated insulin resistance. The KANWU study (n 162; Vessby et al. 2001), one of few human studies to have investigated this area, has found that diets rich in MUFA reduce the adverse effects of diets rich in saturates on insulin sensitivity, although beneficial effects are only seen in diets that provide <37% energy as fat. Further studies are required to confirm these findings and understand the mechanisms involved. LIPGENE is a multi-centred 5-year pan-European project that will study the impact of dietary fat quality and of diet-sensitive genotypes on insulin sensitivity and on risk markers for the metabolic syndrome. Further details of the project are given in accompanying papers in this symposium and can be accessed via www.lipgene.tcd.ie and www.nutrition.org.uk. Studies of the effects of dietary carbohydrate quality, alcohol and achievable exercise regimens on insulin sensitivity are also urgently required. The capability to provide a more individualised approach to diet and lifestyle interventions would also be aided by a better understanding of the interrelationships between diet composition and individual genotypes, and the implications of such interactions on markers of the metabolic syndrome.

**Conclusions**

The prevalence of metabolic syndrome is already high in middle-aged and elderly populations in Europe, and rates are increasing rapidly as a consequence of the predominance of overweight and obesity in most developed
countries. Metabolic syndrome represents an important public health problem, which if left unaddressed has the potential to overwhelm the provision of effective health care in Europe. In the long term the present rise in rates of obesity must be halted and reversed. In the meantime qualitative changes in diet provide a mechanism for reducing the impact of obesity on insulin resistance and metabolic syndrome. Research into the efficacy, mechanisms and means of achieving consistent dietary change is urgently needed.

Acknowledgements

This work was supported by funding from the European Commission, Framework Programme 6 (contract no. FOOD-CT-2003–505944). The authors would also like to thank other members of the LIPGENE team at the University of Reading, Dr Julie Lovegrove, Dr Rachel Gitau and Dr Anne-Marie Minihane for their stimulating discussions.

References


